A comprehensive view of Non-Vaccine Biologics. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA clears Bristol Myers Squibb’s Breyanzi lisocabtagene maraleucel cell therapy to treat large B-cell lymphoma in patients not eligible for stem cell transplant; drug uses genetically modified immune cells that fight cancer
Published: June 28, 2022 by SeeNews Pharmaceuticals
Global regenerative medicine market expected to grow to US$83.19B by 2030, with CAGR growth of 23.4% from 2021 to 2030; growth to be driven by rise in chronic diseases and trauma emergencies, increasing adoption of stem cell technology and nanotechnology
Published: June 27, 2022 by PR Newswire
Cell, gene therapy firm 4basebio collaborating with University of Alabama, Teesside University, to develop treatment for neurofibromatosis Type 1 that causes tumor growth on nerves; 4basebio to develop non-viral Hermes vector, hpDNA sequence as payload
Published: June 15, 2022 by Marketline - Deals
Coeptis Therapeutics receives exclusive option from University of Pittsburgh to license three chimeric antigen receptor T cell technologies that target hematologic, solid tumors; deal includes pre-clinical programs involving breast and ovarian cancer
Published: May 24, 2022 by Marketline - Deals
Ricoh acquires majority stake in biotechnology firm Elixirgen Scientific to accelerate mRNA and personalized drug discovery using Elixirgen’s IPS cell technology; companies to start business predicting drug responses, disease mechanisms using AI
Published: May 19, 2022 by Ricoh Co.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count